OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
Opko Health, Inc. (OPK)
Last opko health, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.opko.com
Company Research
Source: GlobeNewswire
Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of Hematology (ASH) Annual Meeting and ESMO Targeted Anticancer Therapies Congress 2026 WESTON, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced the dosing of patients with its first-in-class tetraspecific T-cell engager, MDX2003, for relapsed or refractory B-cell lymphoma. This multispecific antibody targets two proteins found on the surface of B-cell malignancies, CD19 and CD20, along with the CD3 and CD28 co-stimulatory T-cell activators to sustain T cell killing of these tumors.The MDX-2003-101 study (NCT07249905) is designed to evaluate the safety, tolerability, pharmacokinetic, and immune activity of MDX2003 in adult patients with various types of B-cell lymphoma. The study includes dose-escalation and dose-expansion ph
Show less
Read more
Impact Snapshot
Event Time:
OPK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPK alerts
High impacting Opko Health, Inc. news events
Weekly update
A roundup of the hottest topics
OPK
News
- OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026GlobeNewswire
- GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026 [Yahoo! Finance]Yahoo! Finance
- OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19GlobeNewswire
- Craig-Hallum Reaffirms Buy on GeneDx (WGS) With $153 Price Target [Yahoo! Finance]Yahoo! Finance
- Previvor Edge Expands Platform to Deliver Personalized Clinical-Grade Cancer Risk Profiles and Interactive Prevention Plans [TheStreet.com]TheStreet.com
OPK
Earnings
- 2/26/26 - Beat
OPK
Analyst Actions
- 3/2/26 - Barrington Research
OPK
Sec Filings
- 3/20/26 - Form 4
- 3/20/26 - Form 4
- 3/20/26 - Form 3
- OPK's page on the SEC website